跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

GILEAD SCIENCES INTERNATIONAL LTD.

首页临床试验发起方与机构GILEAD SCIENCES INTERNATIONAL LTD.

GILEAD SCIENCES INTERNATIONAL LTD.

Flowers Building, Cambridge, 英国

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

15

15 进行中

药物批准

4

批准总数

监管机构

2

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

10

66.7%

试验状态分布

进行中（未招募）

15

100.0%

相关临床试验

该机构主办的试验（15）

Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe

进行中（未招募）

Sep 2018100 名受试者

A clinical trial to evaluate the efficacy and safety of sofosbuvir/velpatasvir and ribavirin for 12 weeks in people with hepatitis C infection and liver scarring.

进行中（未招募）

Dec 201732 名受试者

Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe

进行中（未招募）

Dec 2015100 名受试者

Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe

进行中（未招募）

Sep 2015100 名受试者

Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe

进行中（未招募）

Jul 2015100 名受试者

Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe

进行中（未招募）

Jun 201530 名受试者

Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe

进行中（未招募）

Apr 2015100 名受试者

A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL) - ND

进行中（未招募）

Feb 2011354 名受试者

第 1 页，共 2 页

药物批准

按机构分类的批准

EMA

European Medicines Agency

1

药物批准

SFDA

Saudi Food and Drug Authority

3

药物批准

近期批准

VEMLIDY 25MG F.C.TABLET

DESCOVY 200MG/10MG F.C.TABLET

DESCOVY 200MG/25MG F.C.TABLET

资讯

暂无资讯文章

本页目录

概览
相关临床试验15
药物批准4
资讯

返回机构列表